資源描述：
《纈沙坦聯(lián)合貝那普利治療糖尿病腎病療效觀察.doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、纏沙坦聯(lián)合貝那普利治療糖尿病腎病療效觀察［摘要］目的觀察頌沙坦聯(lián)合貝那普利治療糖尿病腎病的療效。方法將20"年1月?2042年1月于我院住院的2型糖尿病腎病患者80例隨機(jī)分為貝那普利組（27例X頌沙坦組（26例X纟頡沙坦聯(lián)合貝那普利組（聯(lián)合組，27例）,三組患者均連續(xù)給予控制血糖和血壓治療2周在此基礎(chǔ)上,三組分別采用貝那普利、頌沙坦、纟頡沙坦聯(lián)合貝那普利治療,均連續(xù)治療12周。對(duì)所有患者的血壓、空腹血糖（FPGX血清電解質(zhì)（K+X血尿素氮（BUN）及血肌軒（SCr肌軒清除率（Ccr）及24h尿蛋白進(jìn)行觀察，同時(shí)記錄不良反應(yīng)。結(jié)果三組治療前后血壓、24h尿蛋白治療后與治療前比較
2、，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）,治療后聯(lián)合組與與貝那普利組、纟頡沙坦組比較，差異有統(tǒng)計(jì)學(xué)意義（P<0.05L三組治療前后FPG、K+、BUN、SCr、Ccr及不良反應(yīng)的比較差異均無統(tǒng)計(jì)學(xué)意義（P>0.05）b結(jié)論纟頡沙坦聯(lián)合貝那普利治療糖尿病腎病患者的血壓、尿蛋白方面療效較單一用藥好，臨床可安全應(yīng)用。［關(guān)鍵詞］纟頡沙坦；貝那普利；糖尿病腎?。慌R床療效［中圖分類號(hào)］R587.2;R692.3［文獻(xiàn)標(biāo)識(shí)碼］A［文章編號(hào)］1673-7210(2012)07(b)-0065-02ClinicalobservationofValsartancombinedwithBenazepri
3、linthetreatmentofdiabeticnephropathyLIXionglCHENTing2CAIDelZHONGZhi1DepartmentofPharmacy,theAffiliatedHospitalofGuangdongMedicalCollege,GuangdongProvince,Zhanjiang524001,China;2.DepartmentofNephrology,theAffiliatedHospitalofGuangdongMedicalCollege,GuangdongProvince,Zhanjiang524001,China［Abst
4、ract］ObjectiveToobservetheeffectofValsartancombinedwithBenazeprilinthetreatmentofdiabeticnephropathy.Methods80patientswithdiabeticnephropathyfromJanuary2011toJanuary2012inourhospitalweredividedintothreegroups:Valsartangroup(27cases),Benazeprilgroup(26cases),ValsartancombinedwithBenazeprilgro
5、up(combinedgroup,27cases).Threegroupsofpatientswerecontinuouslygiventocontrolbloodsugarandbloodpressuretreatmentfor2weeks,onthebasis,Valsartan,Benazeprilandcombineddrugsweregiventhethreegroups,andthetotaltimeofthetreatmentwas12weeks?Andbloodpressure,fastingplasmaglucose(FPG),serumelectrolyte
6、s(K+),bloodureanitrogen(BUN)andserumcreatinine(SCr),creatinineclearancerate(Ccr)and24hurinaryproteinforallpatientswereobserved,andtheadversereactionswererecorded.ResultsBeforeandaftertreatmentinthreegroups,bloodpressure,24hurinaryproteinaftertreatmentwerecompared,thereweresignificantdifferen
7、ces(P<0.05),thecombinedgroupcomparedwiththeBenazeprilgroupandValsartangroup,thereweresignificantdifferences(P<0.05).FPG,K+,BUN,andSCrandCcrandadversereactionsinthethreegroupsbeforeandaftertreatmentshowednosignificantdifferences(P>0.05).ConclusionVa
